Aims-To further define the specificity of the antimucin core antibody C595 by fitting it with a family ofhexapeptide ligands by immunoselection of filamentous bacteriophage from a gene III display library of approximately 6-4 x 107 random hexapeptides. Methods-Three rounds of immunoselection were used to enrich for C595 binding phage. DNA sequencing revealed the hexapeptides expressed. Bacteriophage and corresponding synthetic hexapeptides were used in ELISA assay to determine binding affinities. Human polymorphic epithelial mucins (PEM; MUC 1 mucin; carcinoma associated epithelial mucin) are complex high molecular mass glycoproteins with lubricant and anti-infective properties in normal epithelium, but which are also present in altered forms in human breast carcinoma and other carcinomas.' The PEM show genetic polymorphism evident at the DNA and protein level.23 They comprise a single chain polypeptide core, which consists predominantly of a highly conserved tandem repeat of a 20 amino acid sequence.3 Oligosaccharide side chains are attached in 0-glycosidic linkage to serine and threonine residues of the core, and differences in the glycosylation status of the mucins in neoplasia have been implicated in their recognition by tumour selective monoclonal antibodies.' Recently Price et al,4 by synthesising multiple overlapping heptapeptides, have identified a tumour specific PEM epitope RPAP (arginineproline-alanine-proline) recognised by a murine monoclonal antibody C595. Price et al5 have also delineated the fine specificity of this antibody by comprehensive replacement analysis of individual amino acid residues which comprise the epitope. These studies, using multiple peptide synthesis methodology,6 have provided detailed information about the nature of the epitope recognised by C595, and established the important contribution of R and P residues at the epitope boundary as determinants of binding. All of the peptides identified were analogues of the natural epitope which contained the critical RXXP motif.
Human polymorphic epithelial mucins (PEM; MUC 1 mucin; carcinoma associated epithelial mucin) are complex high molecular mass glycoproteins with lubricant and anti-infective properties in normal epithelium, but which are also present in altered forms in human breast carcinoma and other carcinomas. ' The PEM show genetic polymorphism evident at the DNA and protein level.23 They comprise a single chain polypeptide core, which consists predominantly of a highly conserved tandem repeat of a 20 amino acid sequence.3 Oligosaccharide side chains are attached in 0-glycosidic linkage to serine and threonine residues of the core, and differences in the glycosylation status of the mucins in neoplasia have been implicated in their recognition by tumour selective monoclonal antibodies.' Recently Price et al,4 by synthesising multiple overlapping heptapeptides, have identified a tumour specific PEM epitope RPAP (arginineproline-alanine-proline) recognised by a murine monoclonal antibody C595. Price et al5 have also delineated the fine specificity of this antibody by comprehensive replacement analysis of individual amino acid residues which comprise the epitope. These studies, using multiple peptide synthesis methodology,6 have provided detailed information about the nature of the epitope recognised by C595, and established the important contribution of R and P residues at the epitope boundary as determinants of binding. All of the peptides identified were analogues of the natural epitope which contained the critical RXXP motif.
As an independent means of assessing the epitope specificity of C595 we have applied the approach of Scott and Smith. By comparing the multiple synthetic peptide route and "epitope display library" methods using a well characterised antibody (C595) it should therefore prove feasible to assess the accuracy of the phage display technique for identifying a known epitope, its high affinity substitution variants, and potential mimotope sequences. This will help evaluate the potential for routine use of epitope libraries for the identification of essential contact residues in the epitope-paratope interaction. In addition it is possible to evaluate whether the phage library technique has the capacity to identify common residues flanking the epitope motif, which might favour epitope presentation and optimal expression of antibody binding activity.
We now report the identification of peptide ligands for C595 by the phage display technique. We find that this method allows delineation of the fine specificity of this antibody in unprecedented detail, and extends the chemical data on the epitope specificity of C595. 7 7, placed in a Nunc 1I5 ml cryopreservation tube (Life Technologies) containing a 6-5 mm etched polystyrene ball of 1 gg IgG binding capacity (Northumbria Biologicals), and left for two hours at room temperature. Blocking of potential non-specific binding sites was carried out by immersing the ball in TBS + 5% bovine serum albumin (BSA) for 20 minutes. The ball was placed in 300 p1 of TBS+0-05% Tween 20 + 0.1 % BSA (TBS-Tween); 5 pl of the hexapeptide library (5 x 1010 phage) was then added, the tube capped and the mixture incubated at 37°C for three hours with rotation on a blood mixer, to facilitate phage/antibody interaction.
Methods
The ball was then extensively washed with TBS-Tween and transferred to a sterile Nunc tube. Bound phage was eluted using 500,l of elution buffer (0-1 M HCI, pH adjusted to 2-2 with glycine, 1 mg/ml BSA, 0 1 mg/ml phenol red). The ball and buffer were inverted five times in the capped tube, and the buffer then neutralised by the addition of a few microlitres of 0-05 M Tris HC1, pH 8-8. This material containing eluted phage was then concentrated and desalted using Millipore 
Total =29
'Invariant amino acid sequences of vector regions flanking the variable inserts are in lower case letters.
bThe RXXP motif in the hexapeptides is aligned and shaded for comparative purposes.
In order to minimise requirements for virion ssDNA and avoid the problems of variable yields of DNA from fUse5, cycle sequencing was carried out using a commercially available kit (USB), with a primer, 5'-ACACT-GAGTTTCGTCACCAGT-3' (Oswel DNA Service), to target the 3' end of the hexamer encoding region of pIII. This primer was sited so as to incorporate seven molecules of (c-35S)dATP during the extension stage of the reaction, in order to enhance later reading of the sequence.
Cycle sequencing was carried out on a Hybaid "Omnigene" thermal cycler. The programme was set to act as follows: labelling reaction: 50 cycles of 95°C, 15 s; 55°C, 30 s. This was followed by a termination reaction comprising 50 cycles of 95°C, 30 s; 70°C, 60 s. All other procedures followed the manufacturers' instructions. Sequencing gels were performed using Bio-Rad equipment.
PHAGE CAPTURE ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) To confirm specific binding of C595 to the clones eluted from the coated polystyrene ball, representative phages containing the sequences seen in the table were propagated in K9 1 Kan, as was a control phage known to contain the irrelevant insert sequence KFRFVG. Following purification, the pellets were suspended in water and protein concentration was determined using a bicinchoninic acid kit (Sigma). Phage concentrations were adjusted using phosphate buffered saline (PBS), 1% BSA, 0 05% Tween 20 as diluent by appropriate serial dilutions in the range of 0 05 to 100 p.g/ml.
A microtitre plate (Nunc) was coated with C595 at a concentration of 10 jig/ml in PBS. To obtain a value for maximum C595/AK-CG binding, wells containing no peptide were also present on the microtitre plate, as were blank wells containing no peptide on C595, but coated with AK-CG only.
Following applications of peptide and C595, the plate was vigorously shaken for two minutes to ensure uniform mixing of C595 and peptides.
After one hour at room temperature, the plate was washed four times with PBS-BSATween; 50,l of sheep anti-mouse IgG conjugated to alkaline phosphatase (Sigma) was then added and incubated for one hour. After Phage concentration (jg/ml) B 6&4 x 105 for rounds 1, 2, and 3 respectively. Affinity selected phages obtained after the third round of panning were maintained as tetr K91 Kan transformants and 29 were picked at random for further analysis.
DNA SEQUENCING AND EXPRESSED PEPTIDE ANALYSIS
The DNA sequence of the gene III insert of each phage clone was determined. From this the codon usage and amino acid sequence of the displayed hexamer peptide inserts could be deduced. These are presented in the table.
It is striking that 28 of 29 clones examined contained an RXXP motif, and this is indicated in the table. These sequences can be further subdivided by similarity at both the DNA and protein level. The 29 clones represent nine different DNA sequences, and thus nine unique members of a hexamer peptide display library.
Seven of 29 clones encoded peptide hexamers containing the natural motif RPAP. These originate from two separate DNA sequences. The hexamer RVRPAP actually presents the RXXP motifin two separate "registers" (RVRPAP and RVRPAP). A non-natural motif was most commonly seen, with 17/29 clones (three DNA sequences) expressing peptides with a core motif of RLPP. The most common sequence VRLPPN (9/29) has the RXXP motif in a different "register" (-1 relative to the majority of the hexamers observed) which is seen in only three other clones (two DNA sequences). Only 1/29 clones expressed a com-0 pletely different peptide sequence (KSKAGV).
ANTIBODY BINDING AFFINITY OF BACTERIOPHAGE CLONES
Bacteriophages were prepared and isolated from each transformed K91 kan host. Titration of purified phage against immobilised C595 antibody in ELISA revealed a range of binding affinities ( fig 1A) . Of the phages tested, only KSKAGV and the control negative phage (expressing KFRFVG) showed very low binding affinity to C595. In titration with an irrelevant antibody (791T/36) the specific nature of the affinity of the selected phage displayed peptides is revealed, none binding significantly to this antibody (fig 1B) . In order to study the specificity of these displayed peptides in more detail, the hexamer sequences expressed by three phages were chemically synthesised in order to test their ability to inhibit binding of C595 to a known antigen (AK-CG) containing the C595 target motif RPAP. In addition a hexamer sequence from the native antigen (DTRPAP) was also synthesised. The inhibition curves obtained are shown in fig 2. A negative control peptide APTPGRR which was not expected to bind to C595 shows, as expected, no inhibition until high concentrations are used. By contrast, the peptides containing phage derived sequence show inhibitory activity, with 50% inhibition concentrations (Cl50%) from approximately I0 -molar (RVRPAP) up to i0 -molar (KSKAGV). Peptide RVRPAP inhibits antibody binding significantly better than the natural epitope DTRPAP (CI50% 2 x 1 0-M). The fact that KSKAGV does inhibit C595 binding to AK-CG suggests it is a true peptide ligand, but of low affinity.
Discussion
The sequence of the 20 amino acid tandem repeat core of the MuC-1 PEM containing the C595 reactive epitope is PDTRPAPGS-TAPPAHGVTSA. 3 The importance of the arginine and proline residues in the C595 epitope, as found by Price et al' using synthetic methods, is fully confirmed in the present study.
Twenty nine characterised individual phage clones, resolved to eight independent hexamer sequences at the DNA level, were found to encode the RXXP motif ( no measurable contribution of glycine to antigenicity. However, the constraints upon conformation imposed by pin display and phage display may differ, and perhaps the conformational flexibility afforded by glycine is more important in the phage construct, in allowing the epitope to assume its appropriate conformation.
A further feature of the clones analysed is the presence of either valine (V) or isoleucine (I) at position 1 relative to the RXXP motif. This is seen in 24/28 clones, corresponding to 6/8 unique DNA sequences. These residues are more hydrophobic than the native threonine (T) found at that position; however, all three amino acids possess a methyl (-CH3) group attached to the first carbon of the side chain. This suggests that a methyl group presented at this position may also play a part in determining the binding characteristics of C595. It is interesting that in the phage clones examined the motifs RAAP and RPPP, which were recognised as strongly by C595 as was the native RPAP motif when examined by tetramer synthetic peptide means,'3 were not found. This may be a statistical phenomenon, reflecting the number of clones examined, but may equally be further evidence that the flanking amino acids play an important role in presentation the RXXP motif to the antibody. Wreschner et al '4 indicate that the RPPP sequence may be encoded in place of RPAP in the PEM by alternative splicing of gene transcripts. Our data suggest, purely by the absence of clones, that C595 does not strongly bind the motif RPPP when presented in the context of other, flanking, residues.
A ninth independent phage clone displayed the peptide KSKAGV. This sequence bears no strong resemblance to either the "natural" MUC 1 peptide or to any of the other peptide ligands identified. KSKAGV may, however, be somewhat analogous to the natural epitope, this being inferred by hydrophobicity patterns in DTRPAP and KSKAGV. DTR is comprised of three hydrophilic residues; similarly KSK is hydrophilic, whereas PAP and AGV are comprised of neutral or moderately hydrophobic residues.
The antigenicity of the human polymorphic epithelial mucins is of interest from the point ofview ofvaccine development. Thus synthetic carbohydrate and peptide epitopes of this mucin have been used to provoke antitumour immunity in patients with breast cancer. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] However a fundamental problem with the elicitation of immune responses against tumour antigens is that these antigens are protected by immunological tolerance of self components. Since in the present study we have identified a series of analogues which are antigenically equivalent to the natural mucin epitope recognised by antibody C595, and also a mimotope sequence which is structurally different from the natural epitope, this knowledge may be applied to enhance the immunogenicity of mucin vaccine immunogens. It is possible that the approach described here could be used to generate a library of analogues and mimotopes of mucin epitopes which could be used in the M140 further development of therapeutic vaccines against cancer.
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